PERFORMRx℠

Drug Information Update

November 2022

TABLE OF CONTENTS

NEWLY AVAILABLE GENERICS

Generic Name/ Dosage Form	Brand Name	Manufacturer	Indication
Levamlodipine 2.5 mg oral tablet	Conjupri	CSPC Ouyi	For the treatment of hypertension
Pralatrexate 20 mg/mL, 40 mg/2 mL IV vial	Folotyn	Acrotech Biopharma	For the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
Penciclovir 1% cream	Denavir	Mylan	For the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age or older
Levothyroxine sodium 100 mcg/mL IV vial	Levothyroxine sodium	Leucadia/Hikma	For the treatment of myxedema coma

NEW DRUG ENTITIES/STRENGTHS/COMBINATIONS

Drug Name	Generic Name	Description	Comments
Tecvayli 10 mg/ml, 90 mg/mL subcutaneous solution	teclistamab-cqyv	Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This is approved under accelerated approval based on response rate and is contingent upon clinical benefit in confirmatory trials.	New entity
Lytgobi 4 mg tablet	futibatinib	New entity for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. This underwent accelerated approval; continued approval is contingent upon verification and description of a clinical benefit in confirmatory trials.	New entity
Imjudo 20 mg/mL intravenous solution	tremelimumab-actl	New entity indicated in combination with Imfinzi (durvalumab) for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).	New entity
Moderna COVID-19 Bivalent Boost (6m-5y)(PF) 10 mcg/0.2 mL IM suspension	COVID-19 vaccine, bivalent (Moderna)/PF	Bivalent booster dose for pediatric patients 6 months to 5 years of age (was previously 6 years and older).	New age range, 6 months through 5 years with Emergency Use Authorization
Pfizer COVID-19 Bivalent Vaccine (6m-4y)(PF) 3 mcg/0.2 mL IM suspension	COVID-19 vaccine, bivalent (Pfizer)/PF	Bivalent booster dose for pediatric patients 6 months to 4 years of age (was previously 5 years and older).	New age range, 6 months through 4 years with Emergency Use Authorization

Drug Name	Generic Name	Description	Comments
Xelstrym 4.5 mg, 9 mg, 13.5 mg, 18 mg transdermal patch	dextroamphetamine	New transdermal dosage form of dextroamphetamine.	New entity
Menveo A-C-Y-W-135-Dip (PF) 10 mcg-5 mcg/0.5 mL IM solution	meningococcal vaccine (groups A,C,Y,W-135), diphtheria/PF	New dosage form of meningococcal vaccine that does not require reconstitution.	New dosage form
levothyroxine 100 mcg/mL intravenous solution	levothyroxine sodium	IV dosage form of levothyroxine 100 mcg/mL	New strength, dosage form
Noxafil 300 mg DR oral suspension packet	posaconazole	New dosage form of posaconazole 300 mg as a packet for oral suspension.	New dosage form
methylphenidate 45 mg, 63 mg ER tablet	methylphenidate hcl	New strength of generic methylphenidate ER (Concerta). Was previously only available as 18, 27, 36, and 54 mg ER tablets.	New dosage form, strength
Giapreza 0.5 mg/mL intravenous solution	angiotensin ii acetate, human	New strength of this product indicated for septic shock or other vasodilatory shock states. Was previously only available in 2.5 mg/mL vials.	New strength
Elahere 5 mg/mL intravenous solution	mirvetuximab soravtansine-gynx	Folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Product underwent accelerated approval; continued approval is contingent upon a clinical beneift in a confirmatory trial.	New entity

NEW INDICATIONS (EXISTING DRUGS)

†**Bolded** items reflect newly approved indication; ~~strikethrough~~ of removed indication/age limit/etc.

Brand Name	Generic Name/ Dosage Form	Manufacturer	Newly Approved Indication†
Imfinzi	durvalumab 500 mg/10 mL, 120 mg/2.4 mL IV solution	AstraZeneca	• For the treatment of adult patients with unresectable, stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy • In combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) • In combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) • **In combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC)**
Cotellic	cobimetinib fumarate 20 mg oral tablet	Genentech	• For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib • **As a single agent for the treatment of adult patients with histiocytic neoplasms**
Enhertu	fam-trastuzumab deruxtecan-nxki 100 mg IV vial	Daiichi Sankyo	HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: • Adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either: o in the metastatic setting, or o in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy • Adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed

Brand Name	Generic Name/ Dosage Form	Manufacturer	Newly Approved Indication†
			disease recurrence during or within 6 months of completing adjuvant chemotherapy • **Adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy** o **This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.** • Adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen
Libtayo	cemiplimab-rwlc 350 mg/7 mL vial	Regeneron	Programmed death receptor-1 (PD-1) blocking antibody indicated for: • Cutaneous Squamous Cell Carcinoma (CSCC): For the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation • Basal Cell Carcinoma (BCC): o For the treatment of patients with locally advanced BCC (laBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate o For the treatment of patients with metastatic BCC (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate ▪ The mBCC indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for mBCC may be contingent upon verification and description of clinical benefit. • Non-Small Cell Lung Cancer (NSCLC):

Brand Name	Generic Name/ Dosage Form	Manufacturer	Newly Approved Indication†
			○ **In combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic** ○ As single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic
Adcetris	brentuximab vedotin 50 mg IV vial	Seattle Genetics	CD30-directed antibody-drug conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine • **Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide** • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral Tcell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone

Brand Name	Generic Name/ Dosage Form	Manufacturer	Newly Approved Indication†
			• Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy
Liletta	levonorgestrel-releasing intrauterine system 20.1 mcg/24 hours IUD	Medicines360	For prevention of pregnancy for up to ~~6~~ **8** years
Trulicity	dulaglutide 0.75 mg/0.5 ml, 1.5 mg/0.5 ml, 3 mg/0.5 ml, 4.5 mg/0.5 ml SQ pen	Eli Lilly	• As an adjunct to diet and exercise to improve glycemic control in adults **and pediatric patients 10 years of age and older** with type 2 diabetes mellitus • To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors
Pemetrexed	Pemetrexed 100 mg vial, 500 mg vial, 500 mg/20 ml vial, 1 gram/40 ml vial, 100 mg/4 ml vial	Eagle Pharms	• In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC) • As a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy • As a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy • **In combination with cisplatin for the initial treatment, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery**

FDA DRUG SAFETY COMMUNICATIONS

[11/22/2022] FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

May necessitate increased blood calcium monitoring

The U.S. Food and Drug Administration (FDA) is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine Prolia (denosumab). Our review of interim results from an ongoing safety study of Prolia suggests an increased risk of hypocalcemia, or low calcium levels in the blood, in patients with advanced kidney disease. Preliminary results from a separate internal FDA study further investigating hypocalcemia in dialysis patients treated with Prolia show a substantial risk with serious outcomes, including hospitalization and death.

Because of the frequency and seriousness of these risks, we are alerting health care professionals and patients about them and that we are continuing to evaluate this potential safety issue with Prolia use in patients with advanced kidney disease, particularly those on dialysis. We will communicate our final conclusions and recommendations when we have completed our review or have more information to share.

Patients should not stop Prolia treatment without first consulting your health care professional, as stopping may worsen your bone condition. Talk to your health care professional about any concerns you may have, including possible alternative treatments. Tell your health care professional if you experience any symptoms of low blood calcium levels such as unusual tingling or numbness in the hands, arms, legs, or feet; painful muscle spasms or cramps; voice box or lung spasms causing difficulty breathing; vomiting; seizures; or irregular heart rhythm.

Health care professionals should consider the risks of hypocalcemia with the use of Prolia in patients on dialysis. When Prolia is used in these patients, adequate calcium and vitamin D supplementation and frequent blood calcium monitoring, possibly more often than is already being conducted, may help decrease the likelihood or severity of these risks. Advise patients on dialysis to immediately seek help if they experience symptoms of hypocalcemia.

Prolia is a prescription medicine approved in June 2010 to treat postmenopausal women with osteoporosis at high risk for bone fracture. Prolia was later approved to treat men with osteoporosis, glucocorticoid induced osteoporosis, bone loss in men receiving androgen deprivation therapy for prostate cancer and in women receiving aromatase inhibitor therapy for breast cancer. Prolia works by blocking a protein called RANK (receptor activator of nuclear factor kappa beta) and helps prevent bone cells called osteoclasts from breaking down bone in the body. A health care professional administers Prolia by injection once every six months.

When FDA first approved Prolia, we required the manufacturer, Amgen, to conduct a long-term safety study in women with postmenopausal osteoporosis and men with osteoporosis. Our review of the interim results from this ongoing safety study suggests an increased risk of hypocalcemia with Prolia in patients with advanced kidney disease. In addition, adverse event reports submitted to FDA showed severe and symptomatic hypocalcemia, including hospitalization and death, is occurring in patients with advanced kidney disease treated with Prolia. Preliminary results from a separate internal FDA study investigating the risk of hypocalcemia suggest that patients on dialysis treated with Prolia are at substantial risk for severe and symptomatic hypocalcemia, including hospitalization and death.

We urge health care professionals and patients to report side effects involving Prolia or other medicines to the FDA MedWatch program.

Health care professionals, patients, and consumers can sign up for email alerts about Drug Safety Communications on medicines or medical specialties of interest to you.

RECALLS

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
Atenolol Tablets, USP, 25 mg, 1000-count bottle, Rx only, Manufactured by: ALPHAPHARM PTY LTD, Marketed by: GSMS, Incorporated, Camarillo, CA 93012, USA, NDC 60429-027-10	Class I	Drugs	Lot #: GS046745, Exp 12/2023	Label Mix - up; a bottle labeled as Atenolol 25mg Tablets contained Clopidogrel 75mg Tablets	Golden State Medical Supply Inc.
8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) 50 mL Single Dose Vials, packaged in cartons of 20 vials, Rx only, Manufactured and Distributed by: Exela Pharma Sciences, LLC Lenoir, NC 28645. Carton NDC 51754-5001-5, vial NDC 51754-5001-1	Class I	Drugs	Lot # : P0001370, P0001371, P0001372, Exp. 10/2023; P0001433, P0001434 Exp. 11/2023; P0001443, P0001468, P0001469, P0001470, P0001495, P0001505, P0001506, P0001509, P0001510, P0001511, P0001512 Exp. 12/2023; P0001560, P0001561, P0001562, P0001564, P0001566, P0001567, P0001568 Exp. 01/2024; P0001571, P0001572, P0001573, P0001574, P0001578, P0001579, P0001580, P0001583, P0001586, P0001587, P0001588, P0001593, P0001594, P0001610, P0001618, P0001619, P0001654 Exp. 02/2024;	Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration	Exela Pharma Sciences LLC

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
			P0001644, P0001645, P0001646, P0001662, P0001664 Exp. 03/2024; P0001730 Exp. 05/2024.		
8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) 50 mL Single Dose Vials, packaged in cartons of 20 vials, Rx Only, Mfd for: Civica, Inc. Lehi, Utah 84043, Mfd by: Exela Pharma Sciences, LLC, Lenoir, NC 28645, Carton NDC 72572-740-20, vial NDC 72572-740-1.	Class I	Drugs	Lot #: P0001497 Exp. 12/2023; P0001600 Exp. 02/2024; P0001663 Exp. 03/2024	Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration	Exela Pharma Sciences LLC
Octreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutaneous or Intravenous Use, Rx Only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., Made in Italy, NDC: 67457-246-00 (syringe), 67457-246-01 (carton).	Class I	Drugs	Lot #: AJ21002, Exp. 03/2024	Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.	Viatris Inc
Adam's Polishes ALCOHOL BASED HAND SANITIZER, isopropyl alcohol 75% v/v, packaged in a) 4 fl. oz (118) spray bottle, NDC 74943-125-04; b) 8 fl. oz (237 mL) spray bottle, NDC 74943-125-08; c) 1 PINT / 16 fl. oz (475 ml.) spray bottle, NDC 74943-125-16; and d) 1 GALLON / 128 fl. oz. (3,785 ml.) jug, NDC 74943-125-28, Manufactured by B&B Blending, LLC, Northglenn, CO.	Class I	Drugs	Lot: 133475	Chemical Contamination: FDA analysis found 1 lot of Adam's Polishes ALCOHOL BASED HAND SANITIZER isopropyl alcohol 75% v/v to contain methanol.	Adam's Polishes LLC
Fondaparinux Sodium Injection, USP, 7.5 mg per 0.6 mL, Single Dose, Prefilled Syringe, Distributed by: AuroMedics Pharma LLC 279	Class II	Drugs	Lot # CFN200020, EXP Nov. 2022	Subpotent Drug: Out of specification for assay	AuroMedics Pharma LLC

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
Princeton-Hightstown Rd. E. Windsor, NJ 08520. Made in India. NDC 55150-232-10 (carton)NDC 55150-232-00 (syringe)					
Pyridostigmine Bromide Oral Solution, USP 60 mg/5 mL Delivers 5 mL, packaged in 5mL unit-dose cup, Rx only, Dist. by: VistaPharm, NDC 66689-406-01	Class II	Drugs	Lot#: 832400, Exp 08/2023	cGMP Deviations: Out of specification for assay of one of the preservative ingredients.	VistaPharm, Inc.
Quinapril and Hydrochlorothiazide Tablets, USP 20mg/12.5mg, 90 Tablets bottles Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520, Made in India, NDC 65862-162-90	Class II	Drugs	Lots QE2021005-A and QE2021010-A, exp 01/2023	CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.	Aurobindo Pharma USA Inc.
Proton Armor, Anti-Microbial Alcohol-Free Foaming Hand Sanitizer, kills 99.99% of germs, Odor Free, Family Safe, No Gels, Water Based, 24 Hour Germ Protection with Moisturizers for Sensitive Skin, a) 8 oz bottle, b) 32 oz bottle and c) 1.7 fl oz or 50 mL bottle, Supplier details: Ultra Chem Labs, Ontario, CA, Active Ingredients - Benzalkonium Chloride 0.13% (antimicrobial), ULS 8357 0.33% (antimicrobial shield), NDC 79208-001-50.	Class II	Drugs	Batch: 20087131. No Expiration dates Product Code: a) 3020-8 (8 oz) b) 3020-3 (32 oz) c) 3020-5 (1.7 fl oz./50 mL)	Chemical Contamination and CGMP Deviations: trace amounts of methanol found in one of the components during the manufacturing process.	Ultra Chem Labs Corp
Proton Armor, Anti-Microbial Alcohol-Free Foaming Hand Sanitizer, kills 99.99% of germs, Green Tea and Aloe, Family Safe, No Gels, Water Based, 24 Hour Germ Protection with Moisturizers for Sensitive Skin, a) 8 oz bottle, b) 32 oz bottle, and c) 1.7 fl oz or 50	Class II	Drugs	Batch 20117206. No Expiration dates Product Code: a) 3030-8 (8 oz) b) 3030-3 (32 oz) c) 3030-5 (1.7 fl oz./50 mL)	Chemical Contamination and CGMP Deviations: trace amounts of methanol found in one of the components during the manufacturing process.	Ultra Chem Labs Corp

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
mL bottle, Supplier details: Ultra Chem Labs, Ontario, CA, Active Ingredients - Benzalkonium Chloride 0.13% (antimicrobial), ULS 8357 0.33% (antimicrobial shield), NDC 79208-001-50.					
ACETYLCYSTEINE OPTH 10% Solution, 15 mL droptainers, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 66895, BUD: 11/19/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
ACETYLCYSTEINE OPTH 5% Solution, 15 mL droptainers, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 66017, BUD: 10/13/2022; 66177, BUD: 10/19/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
AUTOLOGUS TEARS SERUM SOLN FULL STRENGTH, 3 mL droptainers, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 65521, BUD: 10/15/2022; 65545, BUD: 10/15/2022; 65605, BUD: 10/16/2022; 65658, BUD: 10/17/2022; 65733, BUD: 10/21/2022; 65894, BUD: 10/24/2022; 66019, BUD: 10/28/2022; 66120, BUD: 10/30/2022; 66388, BUD: 11/6/2022; 66755, BUD: 11/14/2022; 66870, UD: 11/18/2022; 66928, BUD: 11/19/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
BRILLIANT BLUE G, 0.04% Solution, 2 mL vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 60448 BUD: 10/31/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
CEFTAZIDIME INTRAVITREAL 2.25MG/0.1ML Solution, 0.5 mL syringe, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 65434, BUD: 10/13/2022; 66349, BUD: 11/05/2022; 66868, BUD: 11/18/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
CEFUROXIME INTRAVITREAL SYR 1MG/0.1ML Solution in 1 mL syringe, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 63265, BUD: 01/24/2023; 66085, BUD: 04/03/2023	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
CYCLOSPORIN 0.07% OPTH 0.07% Solution in 10 mL bottles, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 59638, BUD: 11/25/2022; 64261, BUD: 04/30/2023	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
GLYCERIN OPHTHALMIC DROPS 98.5% Solution, 10 mL droptainer, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 65416, BUD: 10/13/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
LAURETH-9 INJ 2% Solution, 30 ML vial, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 66513, BUD: 11/10/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
LIDOCAINE/PHENYLEPHRINE PF SYR 1%/1.5% Solution, 3 mL syringes, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 65972, BUD: 10/27/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
LIDOCAINE EPINEPHRINE BUFFERED 2%/1:1000 Solution, 10 mL syringe, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 66591, BUD: 11/12/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
MEDROXYPROGESTERONE ACETATE 300 MG/ML Suspension, 10 mL vial, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 55786, BUD: 12/31/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
METHYLCOBALAMIN PF 1 ML Injection Solution 5,000 MCG/ML Solution, 1 mL vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 57997, BUD: 02/25/2023; 64941, BUD: 03/08/2023	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
MITOMYCIN INJECTION 0.375 mg/mL SYR, 0.375 mg/mL solution, 1 mL syringe, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 60618, BUD: 5/6/2023; 66536, BUD: 7/8/2023	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
MOXIFLOXACIN PRESERVATIVE FREE SYR, 0.15 mg/0.1 mL, Sterile Solution, 1 mL syringes, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 66470, BUD: 11/10/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
PAP/PHEN/PROSTAG/ATROPINE INJ 150MG/7.5MG/75MCG/1MG bottle solution, 5 mL vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 66369, BUD: 11/06/2022; 66540, BUD: 11/09/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
PAPAVERINE / PHENTOLAMINE / PROSTAGLANDIN 150MG / 2.5MG / 50MCG SOLUTION, 5 mL vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 64409, BUD: 04/08/2023; 60849, BUD: 05/23/2023	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
PAPAVERINE / PHENTOLAMINE / PROSTAGLANDIN INJ 150MG/10MG/100MCG/ BOTTLE SOLUTION, 5 ML vial, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 66576, BUD: 11/09/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
PAPAVERINE / PHENTOLAMINE / PROSTAGLANDIN INJ 75MG/2.5MG/50MCG/ BOTTLE SOLUTION, 5 ML vial, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 65425, BUD: 10/13/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
PAPAVERINE / PHENTOLAMINE / PROSTAGLANDIN INJ 90MG/3MG/29.4MCG/ BOTTLE SOLUTION, 5 ML vial, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 66450, BUD: 11/07/2022; 66527, BUD: 11/09/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
PAPAVERINE / PHENTOLAMINE INJECTION 150MG / 5MG / VIAL SOLUTION, 10 mL vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 55092, BUD: 10/22/2022; 59100, BUD: 10/30/2022; 62038, BUD: 04/08/2023; 66533, BUD: 04/08/2023	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
PAPAVERINE HCL STOCK SOLUTION 30MG/ML SOLUTION, 10 mL vial, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 60552, BUD: 03/12/2023	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
PAPAVERINE/PHENTOLAMINE/PROSTAGLANDIN INJ 150/5/50MCG / VIAL SOLUTION, 10 mL vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 65594, BUD: 10/16/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
PAPAVERINE/PHENTOLAMINE/PROSTAGLANDIN INJ 150MG/5MG/10MCG/VIAL SOLUTION, 5 ML vial, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 65976, BUD: 10/27/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
PHENTOLAMINE 10MG/ML INJECTION, 10MG/ML SOLUTION, 10 mL vial, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 60586, BUD: 11/01/2022; 64203, BUD: 01/28/2023	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
PRED ACETATE / GATIFLOXACIN 1% / 0.5% SUSP, 10 mL droptainers, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 65056, BUD: 11/18/2022; 66246, BUD: 11/19/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
PROSTAGLANDIN E1 INJECTION SOLUTION 500MCG/ML SOLUTION, 1 ML vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 59993 BUD: 10/18/2022; 60932 BUD: 11/09/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
SEMAGLUTIDE INJECTION 5MG/ML (0.25MG/0.05ML) SOLN, various amounts in unit dose vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 65680, BUD: 10/11/2022; 66043, BUD: 10/15/2022; 66372, BUD: 10/23/2022; 66597, BUD: 10/29/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
SERUM TEARS IN NSAL 20% OPTH SOLUTION, 3 mL droptainers, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 65490, BUD: 10/14/2022; 65584, BUD: 10/16/2022; 66013, BUD: 10/28/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
TALC, STERILE POWDER, 5 GM vial, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 65995, BUD: 10/28/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
VANCOMYCIN INTRAVITREAL 1MG/0.1ML SOLUTION, 0.5 mL syringes, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lots: 65432, BUD: 10/13/2022; 66347, BUD: 11/05/2022; 66864, BUD: 11/18/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
VORICONAZOLE OPTH SOLUTION 2% STERILE SOLN, 10 ML droptainer, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402	Class II	Drugs	Lot: 66757, BUD: 10/14/2022	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-	Class II	Drugs	Lot #: DNC1129A, Exp 06/2023 Lot #: DNC1740A, Exp 09/2023	Presence of Foreign Substance	SUN PHARMACEUTICAL INDUSTRIES INC

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
396 191, (U.T. of D & NH), India; NDC 62756-970-83					
Carvedilol Tablets, USP, 25 mg, 500-count bottles, Rx Only, Mfg: Mylan Pharmaceuticals Inc. Morgantown, WV 36505, Made in India, NDC 0378-3634-05	Class II	Drugs	Lot #: 3150116, Exp 2/2025	Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.	Viatris Inc
Adam's Polishes ALCOHOL BASED HAND SANITIZER, isopropyl alcohol 75% v/v, packaged in a) 4 fl. oz (118) spray bottle, NDC 74943-125-04; b) 8 fl. oz (237 mL) spray bottle, NDC 74943-125-08; c) 1 PINT / 16 fl. oz (475 ml.) spray bottle, NDC 74943-125-16; and d) 1 GALLON / 128 fl. oz. (3,785 ml.) jug, NDC 74943-125-28, Manufactured by B&B Blending, LLC, Northglenn, CO.	Class II	Drugs	Lots: 133470, 133471, 133472, 133473, 133474, 133476, 133477, 133478, 133479, 133480, 133481, 133482, 133483, 137731, 137732, 137733, 137734, 139322, 143327	CGMP Deviations: Other lots of hand sanitizer are being recalled because they were manufactured under the same conditions as the product lot found to contain methanol.	Adam's Polishes LLC
Phenoxybenzamine Hydrochloride Capsules, USP 10mg, 100-count bottles, RX only Dist. by: Par Pharmaceutical Chestnut Ridge, NY 10977 U.S.A. Mfg. by: Par Forumulations Private Limited,9/215, Pudupakkam, Kelambakkam - 603 103. NDC 49884-038-01	Class II	Drugs	Lot #: 15429401, Exp. Date 08/2023	Failed Impurities/Degradation Specifications	Par Formulations Private Limited
0.9% Sodium Chloride Injection, USP, 100 mL flexible container bag, Rx Only, ICU Medical, Inc., Lake Forest, Illinois, 60045, USA, NDC 0990-7984-37	Class II	Drugs	Lot: 5829936, Exp. MAR 31 2024	Lack of assurance of sterility: Bags have the potential to leak in the flexible containers which may compromise sterility.	ICU Medical Inc
PF-Labetalol HCl Injection, USP 20 mg/4 mL (5 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-946-34, UPC 3 69374 94634 6.	Class II	Drugs	Lots: LB2001B Exp. 01/07/2023; LB2005B Exp. 03/02/2023	CGMP Deviations: Potential for cross contamination due to product carry over.	Nephron Sterile Compounding Center LLC

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-932-33, UPC 3 69374-93233 2.	Class II	Drugs	Lots: NE1062A, NE1062B Exp. 12/02/2022; NE1065A, NE1065B Exp. 12/13/2022; NE2011A, NE2011B Exp. 03/15/2022.	CGMP Deviations: Potential for cross contamination due to product carry over.	Nephron Sterile Compounding Center LLC
Timolol-Latanoprost (0.5/0.005%) ophthalmic drops, Compounded, 5 mL bottle, Imprimis Rx, Ledgewood, NJ.	Class II	Drugs	Lot # 06272022@3, Exp. date 11/24/2022 Lot # 08302022@1, Exp. date 01/27/2023	Subpotent Drug: The batches contain less than 90% of the labeled amount of latanoprost.	ImprimisRx NJ
Pantoprazole Sodium for Delayed-Release Oral Suspension*40 mg* suspension in apple juice or applesauce only Each packet contains 40 mg pantoprazole equivalent to 45.1 mg of pantoprazole sodium USP (sesquihydrate), Rx Only, distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, manufactured by: Sun Pharmaceutical Industries Limited Mohali, INDIA, NDC 62756-071-60	Class II	Drugs	Lot #: MHC1317A, Exp 07/2023	Discoloration	SUN PHARMACEUTICAL INDUSTRIES INC
Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial and One Susvimo initial fill needle, NDC 50242-078-55; and b) carton labeled as Susvimo Ocular Implant with Insertion Tool Assembly, containing One carrier with implant and One insertion Tool, UDI 81004259001, GTIN 00810042590014, Rx only, Genentech, Inc.,	Class III	Drugs	Lot/Exp: a) 3499188, Exp 10/31/2022; Lot 3523071, Exp 6/30/2023; b) 3456735, Exp 10/23/2026; 3456737; Exp 10/29/2026; 3477671, Exp 10/31/2026; 3480781, Exp 12/19/2026; 3506526, Exp 02/25/2027; 3506531, Exp 04/15/2027	Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.	Genentech Inc

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
A Member of the Roche Group, South San Francisco, CA 94080-4990.					
HEPLISAV-B, PFS Hepatitis B Vaccine (Recombinant), Adjuvanted Container Size: 5 doses (5 ml vials) per case Strength: 20MCG/0.5ML Catalog Id 43528-003-05	Class III	Biologics	Lot number 937783 (71 cases & one case = 5 dosages; Total 355 dosages)	McKesson Medical is recalling HEPLISAV-B because it has experienced temperature excursions and was stored at temperatures lower than those specified on the labeling prior to distribution.	Mckesson Medical-Surgical Inc. Corporate Office
Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.	Class III	Drugs	Lot# 6025701, Expiration Date: 31MAR2023, 100mg/vial, 50 ml single use vial, NDC 80803-153-50.	Failed Stability Specifications	Aadi Bioscience
Phenytoin Sodium Injection, USP 100 mg/2 mL, NDC 42192-614-02, packaged in 10 x 2 mL vials per carton, NDC 42192-614-10, Rx only, Manufactured for: Acella Pharmaceuticals, LLC Alpharetta, GA 30005	Class III	Drugs	Lot: E025A001 Exp. 07/2023	Labeling: Not elsewhere classified; the product is being recalled because of customer complaints that the primary vial label was missing a barcode.	Acella Pharmaceuticals, LLC
Phenytoin Sodium Injection, USP, 250 mg/5 mL, NDC 42192-614-05, packaged in 10 x 5 mL vials per carton, NDC 42192-614-30, Rx only, Manufactured for: Acella Pharmaceuticals, LLC Alpharetta, GA 30005	Class III	Drugs	Lot: E026A001 Exp. 06/2023	Labeling: Not elsewhere classified; the product is being recalled because of customer complaints that the primary vial label was missing a barcode.	Acella Pharmaceuticals, LLC

*Please refer to FDA website for further information at: http://www.fda.gov/Safety/Recalls

CURRENT DRUG SHORTAGES

Below is the list of drugs listed by the FDA as currently in shortage. Please refer to the FDA website for more information at: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm

Generic Name or Active Ingredient

Albuterol Sulfate Inhalational Solution
Alprostadil (Muse) Suppository
Amifostine Injection
Amino Acids
Amoxapine Tablets
Amoxicillin Oral Powder for Suspension
Amphetamine; Dextroamphetamine Tablets
Atropine Sulfate Injection
Azacitidine for Injection
Azithromycin (Azasite) Ophthalmic Solution 1%
Bacteriostatic 0.9% Sodium Chloride Injection
Bacteriostatic Water for Injection
Belatacept (Nulojix) Lyophilized Powder for Injection
Belladonna and Opium Suppositories
Bumetanide Injection
Bupivacaine Hydrochloride and Epinephrine Injection
Bupivacaine Hydrochloride Injection
Calcium Disodium Versenate Injection
Calcium Gluconate Injection
Cefazolin Injection
Cefixime Oral Capsules
Cefotaxime Sodium Injection
Cefotetan Disodium Injection
Chloroprocaine Hydrochloride Injection
Collagenase Ointment
Conivaptan Hydrochloride (Vaprisol) in 5% Dextrose Plastic Container
Conjugated Estrogens/Bazedoxifene (DUAVEE) Tablet, Film Coated
Cyclopentolate Ophthalmic Solution
Cytarabine Injection
Dacarbazine Injection
Desmopressin Acetate Nasal Spray
Dexamethasone Sodium Phosphate Injection
Dexmedetomidine Injection
Dextrose 10% Injection
Dextrose 25% Injection
Dextrose 5% Injection
Dextrose 50% Injection
Diazepam Rectal Gel

Diflunisal Tablets
Digoxin Injection
Diltiazem Hydrochloride Injection
Disopyramide Phosphate (Norpace) Capsules
Dobutamine Hydrochloride Injection
Dopamine Hydrochloride Injection
Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution
Enalaprilat Injection
Epinephrine Injection, 0.1 mg/mL
Epinephrine Injection, Auto-Injector
Erythromycin Ophthalmic Ointment
Etomidate Injection
Fentanyl Citrate (Sublimaze) Injection
Floxuridine for Injection
Fludarabine Phosphate Injection
Fluorescein Injection
Flurazepam Hydrochloride Capsules
Fluvoxamine ER Capsules
Furosemide Injection
Gentamicin Sulfate Injection
Guanfacine Hydrochloride Tablets
Heparin Sodium and Sodium Chloride 0.9% Injection
Hydromorphone Hydrochloride Injection
Hydroxypropyl (Lacrisert) Cellulose Ophthalmic Insert
Ibutilide Fumarate Injection
Indigotindisulfonate Sodium Injection
Iomeprol injection
Isoniazid Injection
IV Fat Emulsion
Ketamine Injection
Ketorolac Tromethamine Injection
Leucovorin Calcium Lyophilized Powder for Injection
Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags
Lidocaine Hydrochloride (Xylocaine) Injection
Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine
Lithium Oral Solution
Lorazepam Injection
Mannitol Injection
Mepivacaine Hydrochloride Injection
Methyldopa Tablets
Methylprednisolone Acetate Injection
Metronidazole Injection
Midazolam Injection
Morphine Sulfate Injection
Multi-Vitamin Infusion (Adult and Pediatric)
Neomycin Sulfate Tablets

Nizatidine Capsules
Oxytocin Injection
Paclitaxel Injection (protein-bound particles)
Pantoprazole Sodium for Injection
Parathyroid Hormone (Natpara) Injection
Pentostatin Injection
Physostigmine Salicylate Injection
Potassium Acetate Injection
Potassium Chloride Concentrate Injection
Promethazine (Phenergan) Injection
Remifentanil Injection
Rifampin Capsules
Rifampin Injection
Rifapentine Tablets
Ropivacaine Hydrochloride Injection
Semaglutide (Ozempic) Injection
Semaglutide (WEGOVY®) Injection
Sincalide (Kinevac) Lyophilized Powder for Injection
Sodium Acetate Injection
Sodium Bicarbonate Injection
Sodium Chloride 0.9% Injection Bags
Sodium Chloride 14.6% Injection
Sodium Chloride 23.4% Injection
Sodium Chloride Injection USP, 0.9% Vials and Syringes
Sodium Phosphates Injection
Sterile Water for Injection
Streptozocin (Zanosar) Sterile Powder
Sufentanil Citrate Injection
Sulfasalazine Tablets
Technetium TC-99M Mebrofenin Injection
Technetium TC-99m Sodium Pertechnetate Generator
Technetium Tc99m Succimer Injection (DMSA)
Teprotumumab-trbw
Triamcinolone Acetonide Injectable Suspension
Triamcinolone Hexacetonide Injectable suspension
Trimethobenzamide Hydrochloride Capsules
Valproate Sodium Injection
Vecuronium Bromide for Injection
Verteporfin (Visudyne) Injection